Nader Pourhassan

University of Tehran — IR

Medicine · Health Sciences

10h-index496citations15works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

COVID-19 Clinical Research Studies(6), SARS-CoV-2 and COVID-19 Research(6), HIV Research and Treatment(4), Long-Term Effects of COVID-19(4), HIV/AIDS Research and Interventions(3)

Publications15 total

Performance evaluation of motorlance in the Pre-hospital Emergency System of Tabriz City 2018-2021
Medical Journal of Tabriz University of Medical Sciences·2024Open Access
Road Safety as an Essential Need of Aged Population: A Case of Tabriz City, Iran
International Journal of Aging·2023· 1 citedOpen Access
Abstract CT156: Changes in circulating tumor associated cells predicts progression free and overall survival in metastatic TNBC patients after induction of the anti-CCR5 drug leronlimab
Cancer Research·2022· 1 cited
Safety, efficacy, and clinical outcomes of the anti-CCR5 inhibitor (Leronlimab): A pooled analysis of three clinical trials in patients with mTNBC.
Journal of Clinical Oncology·2022· 11 cited
Reduced Cell Surface Levels of C-C Chemokine Receptor 5 and Immunosuppression in Long Coronavirus Disease 2019 Syndrome
Clinical Infectious Diseases·2022· 27 citedOpen Access
Suppression of human and simian immunodeficiency virus replication with the CCR5-specific antibody Leronlimab in two species
PLoS Pathogens·2022· 15 citedOpen Access
CCR5 Receptor Occupancy Analysis Reveals Increased Peripheral Blood CCR5+CD4+ T Cells Following Treatment With the Anti-CCR5 Antibody Leronlimab
Frontiers in Immunology·2021· 25 citedOpen Access
Antibody-based CCR5 blockade protects Macaques from mucosal SHIV transmission
Nature Communications·2021· 19 citedOpen Access
Disruption of CCR5 signaling to treat COVID-19-associated cytokine storm: Case series of four critically ill patients treated with leronlimab
Journal of Translational Autoimmunity·2021· 61 citedOpen Access
Case study of a critically ill person with COVID-19 on ECMO successfully treated with leronlimab
Journal of Translational Autoimmunity·2021· 10 citedOpen Access
CCR5 inhibition in critical COVID-19 patients decreases inflammatory cytokines, increases CD8 T-cells, and decreases SARS-CoV2 RNA in plasma by day 14
International Journal of Infectious Diseases·2020· 146 citedOpen Access
Abstract CT233: Phase Ib/II study of leronlimab (PRO 140) combined with carboplatin in CCR5+ mTNBC patients
Cancer Research·2020· 7 cited
Disruption of the CCL5/RANTES-CCR5 Pathway Restores Immune Homeostasis and Reduces Plasma Viral Load in Critical COVID-19
2020· 103 citedOpen Access
Disruption of the CCL5/RANTES-CCR5 Pathway Restores Immune Homeostasis and Reduces Plasma Viral Load in Critical COVID-19
Research Square (Research Square)·2020· 21 citedOpen Access
PRO 140, a monoclonal antibody targeting CCR5, as a long-acting, single-agent maintenance therapy for HIV-1 infection
HIV Clinical Trials·2018· 49 cited

Frequent Co-authors

Kush Dhody(8), Jonah B. Sacha(8), Helen L. Wu(7), Scott A. Kelly(7), Gabriela M. Webb(6), Bruce K. Patterson(5), Kazem Kazempour(5), Lishomwa C. Ndhlovu(5), Jay Lalezari(4), Scott G. Hansen(4), Harish Seethamraju(3), Michael J. Corley(3), Alina P.S. Pang(3), Christopher Sugai(3), Edgar B. Francisco(3), Amruta Pise(3), Hallison Rodrigues(3), Byung Park(3), Lama Kdouh(3), Mónica Herrera(3)